The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.
Paul G. Richardson
Consultant or Advisory Role - Celgene; Johnson & Johnson; Millennium
Craig Hofmeister
Consultant or Advisory Role - Celgene
Research Funding - Celgene; Millennium
Noopur S. Raje
Consultant or Advisory Role - Celgene
David Samuel DiCapua Siegel
Consultant or Advisory Role - Celgene; Merck; Millennium; Onyx
Honoraria - Celgene; Merck; Millennium; Onyx
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Millennium; Novartis
Jacob Laubach
Research Funding - Novartis; Onyx
Yvonne Adeduni Efebera
No relevant relationships to disclose
David H. Vesole
Consultant or Advisory Role - Celgene
Honoraria - Celgene; Millennium
Ajay K. Nooka
No relevant relationships to disclose
Jacalyn Rosenblatt
No relevant relationships to disclose
Mohamed H. Zaki
Employment or Leadership Position - Celgene
Ye Hua
Employment or Leadership Position - Celgene
Yan Li
Employment or Leadership Position - Celgene
Sheetal Shah
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Jianming Wang
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Kenneth Carl Anderson
Consultant or Advisory Role - Celgene; Millennium